Table 2.
Medical and Genotyping Information for Prospectively Studied HAdV-Positive Immunocompromiseda Patients Hospitalized in Singapore, 2015–2018
| Total | Pediatricb | Adult | |
|---|---|---|---|
| Variables | n = 22 (%) | n = 3 (%) | n = 19 (%) |
| Gender | |||
| Female | 10 (45.5) | 1 (33.3) | 9 (47.4) |
| Male | 12 (54.5) | 2 (66.7) | 10 (52.6) |
| Clinical Presentation | |||
| Respiratory | 13 (59.1) | 1 (33.3) | 12 (63.2) |
| Gastrointestinal | 7 (31.8) | 2 (66.7) | 5 (26.3) |
| Genitourinary | -- | -- | -- |
| Ocular | 1 (4.5) | 1 (33.3) | -- |
| Other | 2 (9.1) | -- | 2 (10.5) |
| Cause of Immunodeficiency | |||
| End-stage renal failure; diabetes mellitus | 1 (4.5) | -- | 1 (5.3) |
| Stem cell transplant | 5 (22.7) | 1 (33.3) | 4 (21.0) |
| Kidney transplant | 1 (4.5) | -- | 1 (5.3) |
| HIV-positive | 2 (9.1%) | -- | 2 (10.5) |
| Nontransplant/other | 13 (59.1) | 2 (66.7) | 11 (57.9) |
| Disease Severity | |||
| Prolonged hospitalizationc | 17 (77.3) | 3 (100) | 14 (73.7) |
| Prolonged feverd | 2 (9.1) | 1 (33.3) | 1 (5.3) |
| ICU admission | 1 (4.5) | -- | 1 (5.3) |
| HAdV Genotype | |||
| C2 | 1 (4.5) | -- | 1 (5.3) |
| C5 | 1 (4.5) | 1 (33.3 | -- |
| B3 | 4 (18.2) | 1 (33.3) | 3 (15.8) |
| B7 | 3 (13.6) | -- | 3 (15.8) |
| E4 | 4 (18.2) | -- | 4 (21.0) |
| Unknowne | 9 (40.9) | 1 (33.3) | 8 (42.1) |
| Otherf | -- | -- | -- |
Abbreviations: HAdV, human adenovirus; HIV, human immunodeficiency virus; ICU, intensive care unit.
aImmunocompromised within 6 months before clinical sample collection.
bPediatric (≤16 years).
cHospitalized for more than 7 consecutive days.
dFever lasting more than 7 days.
eGenotyping failed.
fHAdV-C1, C6, -B11p, -B21, -B35, -D8, or -D53.